

# Navicixizumab Biosimilar - Research Grade

**Product Code:** ICH6020

**More Information**

**Species Reactivity:** Human

**Target:** VEGFA + DLL4

**Concentration:** 5mg/ml

**Isotype:** Human IgG2(K370E/S378A/K409E/KDeI///E357K/S378A/D399K)-Lambda2

**product name H2:** Navicixizumab Biosimilar - Research Grade

**Sequence:** <https://www.imgt.org/mAb-DB/>

**Buffer:** ICH3002

**UniProt:** P15692;Q9NR61

**Shipping Conditions:** Blue ice

**background:** Tumour angiogenesis is driven jointly by VEGFA signalling and Notch-pathway DLL4, and simultaneously blocking both has been explored to suppress aberrant vessel formation in cancer. This research-grade bispecific antibody is an unconjugated, non-therapeutic analog of navicixizumab, engineered to engage VEGFA and DLL4 for preclinical investigation of dual anti-angiogenic strategies. Validated for functional assays, it is supplied strictly for research use only (RUO). Manufactured to in vivo grade standards as an ultra-pure, low-endotoxin formulation and available in scalable milligram (mg) to gram (g) quantities, it supports heavy-usage and high-throughput laboratories running in vitro screening, in vivo tumour models and dual-pathway angiogenesis characterization.

**Purification Method:** This monoclonal antibody was purified using IEC

**Formulation:** Sterile, preservative-free, solution in PBS. BSA and Azide free.



**Purity:** >90% by SDS-PAGE

**Endotoxin:**  $\leq 1.0$  EU/mg as determined by the LAL method

**Storage:** This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

**Applications:** Functional Assays

**Application Notes:** This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

**Use:** Products are for research use only. Not for use in diagnostic or therapeutic procedures.